I think this will be the norm. When you have something new, there is the theoretical potential for harm. |
I'm a big believer in size, ... When you're a smaller company, as we were 27 years ago when I started, you don't necessarily have the resources to invest in things outside your immediate expertise. But as we've gotten bigger and become more resource-rich we've been able to expand. |
Is the public more cynical? Yes. There's a perception that we don't bring much to the party. |
More than one billion people around the world suffer from neurological conditions and diseases, and finding new, more effective treatments for patients is a high priority for Pfizer research and development. |
We recognize that many diseases we aim to treat have a strong genetic component. Additionally, we know some patients taking medicines show efficacy or experience side-effects, while others do not. Our understanding of all this has improved greatly but these areas remain as significant challenges in drug development. |
We will be the first out there and for a while. |
We're of a size and can do enough different things that we're not putting all our bets on one specific area, |